Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102791 · ClinicalTrials.gov registry record · Phase 3
A Stratified Sickle Event Randomized Trial (ASSERT)
A Phase 3 study, sponsored by Icagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
NCT00102791 is a Phase 3 study that was terminated before completion, run by Icagen. The registered enrollment target is 297 participants.
The verdict
NCT00102791, a Phase 3 study, was terminated before completion, sponsored by Icagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.
Interventions
- DRUG ICA-17043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102791
The ClinicalTrials.gov registry entry for NCT00102791 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icagen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ICA-17043 is the first listed.
NCT00102791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102791 about?
NCT00102791 is a clinical study titled "A Stratified Sickle Event Randomized Trial (ASSERT)". The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility wit...
What is the current status of trial NCT00102791?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2005-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00102791?
The interventions under investigation include: ICA-17043 (DRUG).
Who is sponsoring clinical trial NCT00102791?
This trial is sponsored by Icagen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.